Today's IV Antibiotic Options for Complicated UTI: Strengths and Limitations

"Today's IV Antibiotic Options for Complicated UTI: Strengths and Limitations" surveys the intravenous antibiotics clinicians reach for today, and where each option's limitations show up in practice.

Turning to current intravenous options, Dr. Gupta asks Dr. Pogue to lay out the standard-of-care landscape for hospitalized complicated UTI patients. Dr. Pogue explains that Escherichia coli and other Enterobacterales are the primary targets in most admitted patients. Third-generation cephalosporins like ceftriaxone are the typical first choice, limited by a national extended-spectrum beta-lactamase rate of roughly fifteen to twenty percent among these organisms. He notes that catheter-associated infections, or a history of Pseudomonas, can shift that initial target organism. Aminoglycosides are seeing renewed interest as an upfront option, since dose-optimized, duration-limited use is generally well tolerated outside of acute-kidney-injury risk. Drugs like gentamicin and amikacin retain strong activity against many extended-spectrum beta-lactamase producers, limiting the need for broader-spectrum agents upfront. Carbapenems remain reserved for patients at genuinely elevated resistance risk, such as those with recent heavy cephalosporin or fluoroquinolone exposure or presenting in septic shock. Dr. Gupta then asks Dr. Nelson what challenges arise when the most effective options against multidrug-resistant uropathogens require intravenous administration. Dr. Nelson describes a persistent clinician assumption that intravenous therapy must finish in the hospital, prolonging admissions and exposing patients to healthcare-associated infection risk. Even when patients are medically cleared to leave, outpatient infusion services add cost and access barriers for many. That reinforces a broader misconception that hospitalized patients automatically need extended intravenous courses, even absent multidrug-resistant organisms. Together, the two panelists frame this as a structural gap. Effective therapy exists, but until recently the only reliably effective options for higher-risk uropathogens required intravenous delivery. That requirement ties treatment to hospitalization or costly outpatient infusion infrastructure, regardless of how sick the patient truly was on presentation.

Up next, in "Two New Antibiotics Expand the Complicated UTI Treatment Landscape," the panel unpacks two therapies that are reshaping the complicated UTI treatment landscape.